NewEdge Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.88M | Sell |
7,610
-2,310
| -23% | -$1.77M | 0.02% | 629 |
|
|
2025
Q4 | $7.66M | Buy |
9,920
+5,888
| +146% | +$4M | 0.03% | 514 |
|
|
2025
Q3 | $2.27M | Buy |
4,032
+2,094
| +108% | +$1.18M | 0.01% | 951 |
|
|
2025
Q2 | $1.02M | Sell |
1,938
-102
| -5% | -$56.9K | 0.01% | 1284 |
|
|
2025
Q1 | $1.29M | Sell |
2,040
-760
| -27% | -$523K | 0.01% | 1048 |
|
|
2024
Q4 | $1.99M | Sell |
2,800
-1,630
| -37% | -$1.37M | 0.01% | 829 |
|
|
2024
Q3 | $4.66M | Buy |
4,430
+62
| +1% | +$69K | 0.03% | 504 |
|
|
2024
Q2 | $4.59M | Buy |
4,368
+260
| +6% | +$252K | 0.03% | 474 |
|
|
2024
Q1 | $3.95M | Sell |
4,108
-617
| -13% | -$587K | 0.03% | 466 |
|
|
2023
Q4 | $4.33M | Buy |
4,725
+2,179
| +86% | +$1.79M | 0.04% | 398 |
|
|
2023
Q3 | $2.1M | Sell |
2,546
-1,027
| -29% | -$807K | 0.02% | 586 |
|
|
2023
Q2 | $2.57M | Sell |
3,573
-1,408
| -28% | -$1.09M | 0.03% | 509 |
|
|
2023
Q1 | $4.09M | Buy |
4,981
+962
| +24% | +$726K | 0.05% | 338 |
|
|
2022
Q4 | $2.57M | Buy |
4,019
+1,818
| +83% | +$1.34M | 0.07% | 288 |
|
|
2022
Q3 | $1.52M | Buy |
2,201
+960
| +77% | +$604K | 0.02% | 505 |
|
|
2022
Q2 | $733K | Buy |
+1,241
| New | +$807K | 0.01% | 818 |
|
|
2022
Q1 | – | Sell |
-1,518
| Closed | -$959K | – | 1526 |
|
|
2021
Q4 | $959K | Buy |
1,518
+867
| +133% | +$533K | 0.01% | 754 |
|
|
2021
Q3 | $394K | Buy |
651
+29
| +5% | +$18K | 0.01% | 815 |
|
|
2021
Q2 | $347K | Buy |
622
+8
| +1% | +$4.05K | 0.01% | 841 |
|
|
2021
Q1 | $291K | Sell |
614
-106
| -15% | -$51.6K | 0.01% | 825 |
|
|
2020
Q4 | $348K | Sell |
720
-22
| -3% | -$11.9K | 0.01% | 715 |
|
|
2020
Q3 | $415K | Buy |
742
+118
| +19% | +$71.5K | 0.01% | 627 |
|
|
2020
Q2 | $389K | Sell |
624
-469
| -43% | -$266K | 0.02% | 606 |
|
|
2020
Q1 | $534K | Buy |
1,093
+473
| +76% | +$195K | 0.03% | 438 |
|
|
2019
Q4 | $232K | Buy |
+620
| New | +$209K | 0.01% | 734 |
|
|
2019
Q2 | – | Sell |
-493
| Closed | -$202K | – | 694 |
|
|
2019
Q1 | $202K | Buy |
+493
| New | +$203K | 0.01% | 624 |
|
|
2018
Q4 | – | Sell |
-1,182
| Closed | -$478K | – | 698 |
|
|
2018
Q3 | $478K | Buy |
+1,182
| New | +$450K | 0.04% | 368 |
|
|
2017
Q4 | – | Sell |
-494
| Closed | -$232K | – | 422 |
|
|
2017
Q3 | $232K | Buy |
494
+454
| +1,135% | +$216K | 0.04% | 329 |
|
|
2017
Q2 | $20K | Buy |
+40
| New | +$17.5K | ﹤0.01% | 742 |
|
Other funds holding REGN
VCM
N
NewEdge Advisors's REGN Position: Q1 2026 in Review
NewEdge Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 23% in Q1 2026, selling an estimated $1.77M and leaving 7,610 shares worth $5.88M. The position accounts for 0.02% of the portfolio, ranked #629.
NewEdge Advisors first reported a position in REGN in Q2 2017 and has held it in 29 quarters since. The position peaked at $7.66M in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- NewEdge Advisors held 7,610 shares of Regeneron Pharmaceuticals worth $5.88M as of Q1 2026.
- NewEdge Advisors sold 2,310 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.77M.
- Regeneron Pharmaceuticals made up 0.02% of NewEdge Advisors's portfolio in Q1 2026, its #629 holding.
- NewEdge Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2017 and has held it in 29 quarters since.
- NewEdge Advisors's Regeneron Pharmaceuticals position peaked at $7.66M in Q4 2025.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.